IPCA Labs posted results lower than expected for 2QFY2018 mainly on the OPM and net profit front. In sales, the company posted sales of `864cr, a yoy de-growth of 2.3% v/s. `884cr for 2QFY2017, but mostly in line with the expected sales of `870cr. On OPM front, the company posted EBITDA of 17.2% (v/s. 20.5% expected) v/s. 15.3% in 2QFY2017. Consequently, the company posted a profit of `96cr (v/s. PAT of `109cr expected) v/s. PAT of `55cr in 2QFY2017. We recommend Accumulate with a target of `570.

Download Full Report View Full Report in Browser